Sleep apnea syndrome

Summary

Sleep apnea syndrome (MONDO:0005296) is a disease with 4 cohort genes (60 GWAS associations across 45 studies) and 742 clinical trials. Top therapeutic interventions include acetazolamide, montelukast, and losartan.

At a glance

• Cohort genes: 4
• GWAS associations: 60
• ClinVar variants: 7
• Clinical trials: 742

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	sleep apnea syndrome
Mondo ID	MONDO:0005296
EFO	EFO:0003877
MeSH	D012891
DOID	DOID:0050847
ICD-10-CM	G47.3
NCIT	C148023
SNOMED CT	111489007, 73430006
UMLS	C0037315
MedGen	11458
Is cancer (heuristic)	no

Also known as: apnea syndrome, sleep · apnea syndromes, sleep · apnea, sleep · apneas, sleep · breathing, sleep-disordered · breathing-related sleep disorder · hypersomnia with periodic respiration · hypopnea, sleep · hypopneas, sleep · mixed central and obstructive sleep apnea · mixed sleep apnea · mixed sleep Apneas · SDB · sleep apnea · sleep apnea syndrome · sleep apnea, mixed · sleep apnea, mixed central and obstructive · sleep apneas · sleep apneas, mixed · sleep disordered breathing (+3 more)

Data availability: 7 ClinVar variants · 60 GWAS associations (45 studies) · 1 HPO phenotype.

Disease family

An umbrella term covering 2 Mondo subtypes.

Classification path: disease › human disease › disease by developmental or physiological process › sleep disorder › sleep-wake disorder › sleep apnea syndrome

Related subtypes (11): bruxism, recurrent hypersomnia, hypersomnia, periodic limb movement disorder, REM sleep behavior disorder, autosomal dominant cerebellar ataxia, deafness and narcolepsy, hereditary sensory neuropathy-deafness-dementia syndrome, autoimmune encephalopathy with parasomnia and obstructive sleep apnea, narcolepsy, circadian rhythm sleep disorder, sleep disorder, initiating and maintaining sleep

Subtypes (2): central sleep apnea syndrome, obstructive sleep apnea syndrome

Genetics & variants

GWAS landscape

60 GWAS associations across 45 studies. Top hits map to 27 distinct genes (as reported by GWAS).

Top associations by p-value

rsID	p-value	Gene	Risk allele	Odds ratio
rs1421085	3e-87	FTO	T	0.08
rs11642015	7e-45	FTO	C	0.08
rs13107325	3e-33	SLC39A8	C	0.09
rs6724384	4e-21	LINC01122	C	0.04
rs11075985	5e-20	FTO	?	0.02
rs1389799	1e-18	MSRB3	?	0.04
rs76880877	3e-18	ETV5	A	0.05
rs6265	2e-14	BDNF-AS, BDNF	?	0.02
rs592333	2e-14	DLEU1, DLEU7	?	0.04
rs72902175	4e-14	LINC01876	?	0.04
chr16:53799847	2e-13		G	0.07
rs78785910	2e-13	ETV5	G	0.05
chr1:112318484	2e-12		A	0.03
chr7:5395553	3e-12		T	0.06
chr7:114618505	8e-12		A	0.03
chr7:1896690	1e-11		C	0.04
chr10:77619044	1e-11		C	0.03
rs35445111	2e-11	RNA5SP471 - RNU6-967P	?	0.05
chr6:28831535	2e-11		A	0.05
chr6:98459736	2e-11		A	0.04
chr10:102598860	2e-11		G	0.04
chr3:85428726	3e-11		T	0.03
rs181962217	3e-11	GHITM - CERNA2	T	2.14
chr11:64456099	4e-11		C	0.03
rs13028310	4e-11	LINC01875 - TMEM18	T	0.04
rs6113592	8e-11	LINC01432 - LINC01427	?	0.02
rs4923536	8e-11	METTL15	?	0.03
rs12603115	8e-10	SKAP1	?	0.02
rs1537818	1e-09	MACF1	?	0.02
rs1444789	1e-09	LINC02676 - LINC00709	?	0.04

Top studies (by case count)

Study	Lead author	Year	Cases	Controls	Title
GCST90475824	Verma A	2024	152,031	278,027	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90475257	Verma A	2024	79,571	236,097	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90477485	Verma A	2024	45,335	70,630	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90479999	Verma A	2024	45,335	70,630	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90267361	Campos AI	2022	25,008	337,630	Discovery of genomic loci associated with sleep apnoea risk through multi-trait GWAS analysis with snoring.
GCST90267363	Campos AI	2022	25,008	337,630	Discovery of genomic loci associated with sleep apnoea risk through multi-trait GWAS analysis with snoring.
GCST90475258	Verma A	2024	24,111	291,557	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90477483	Verma A	2024	22,934	34,075	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90624797	Strausz S	2025	20,413	443,463	Genetic associations between Serotonin Receptor 1F (HTR1F) regulatory variation and sleep apnea in non-obese individuals: Insights from GWAS and eQTL analyses.
GCST90476694	Verma A	2024	15,464	40,041	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.

Variant details and genetic-evidence tiers

Tier distribution (top 50 variants)

Tier	Variants
Tier 1: coding	3
Tier 2: splice/UTR	1
Tier 3: regulatory	2
Tier 4: intronic/intergenic	44

MAF distribution

Bucket	Variants
common (>=0.05)	48
low_freq (0.01-0.05)	0
rare (<0.01)	1
unknown	1

Functional consequences

Consequence	Count
intron_variant	23
unknown	12
intergenic_variant	8
missense_variant	2
regulatory_region_variant	2
3_prime_UTR_variant	1
synonymous_variant	1
stop_gained	1

Top variants

rsID	Chr	Pos	Alleles	MAF	Consequence	Gene	p-value	Tier
rs1421085	16	53767042	T>C	0.408	intron_variant	FTO	3e-87	Tier 4: intronic/intergenic
rs11642015	16	53768582	C>G,T	0.404	intron_variant	FTO	7e-45	Tier 4: intronic/intergenic
rs13107325	4	102267552	C>A,T	0.083	missense_variant	SLC39A8	3e-33	Tier 1: coding
rs6724384	2	58652358	C>T	0.412	intron_variant	LINC01122	4e-21	Tier 4: intronic/intergenic
rs11075985	16	53771295	C>A	0.05	intron_variant	FTO	5e-20	Tier 4: intronic/intergenic
rs1389799	12	65431066	A>C,G,T	0.05	intron_variant	MSRB3	1e-18	Tier 4: intronic/intergenic
rs76880877	3	186084839	A>C	0.134	intron_variant	ETV5	3e-18	Tier 4: intronic/intergenic
rs6265	11	27658369	C>A,G,T	0.05	missense_variant	BDNF-AS, BDNF	2e-14	Tier 1: coding
rs592333	13	50766179	A>G,T	0.05	regulatory_region_variant	DLEU1, DLEU7	2e-14	Tier 3: regulatory
rs72902175	2	156156523	C>A,T	0.05	intron_variant	LINC01876	4e-14	Tier 4: intronic/intergenic
chr16:53799847				0.426			2e-13	Tier 4: intronic/intergenic
rs78785910	3	186094845	G>A	0.143	intron_variant	ETV5	2e-13	Tier 4: intronic/intergenic
chr1:112318484				0.38			2e-12	Tier 4: intronic/intergenic
chr7:5395553				0.165			3e-12	Tier 4: intronic/intergenic
chr7:114618505				0.453			8e-12	Tier 4: intronic/intergenic
chr7:1896690				0.194			1e-11	Tier 4: intronic/intergenic
chr10:77619044				0.489			1e-11	Tier 4: intronic/intergenic
rs35445111	19	31681141	A>G	0.05	intron_variant	RNA5SP471 - RNU6-967P	2e-11	Tier 4: intronic/intergenic
chr6:28831535				0.101			2e-11	Tier 4: intronic/intergenic
chr6:98459736				0.121			2e-11	Tier 4: intronic/intergenic
chr10:102598860				0.126			2e-11	Tier 4: intronic/intergenic
chr3:85428726				0.456			3e-11	Tier 4: intronic/intergenic
rs181962217	10	84156277	T>A	0.001	intergenic_variant	GHITM - CERNA2	3e-11	Tier 4: intronic/intergenic
chr11:64456099				0.305			4e-11	Tier 4: intronic/intergenic
rs13028310	2	632591	T>A,C,G	0.186	intergenic_variant	LINC01875 - TMEM18	4e-11	Tier 4: intronic/intergenic
rs6113592	20	22248867	A>G	0.05	intergenic_variant	LINC01432 - LINC01427	8e-11	Tier 4: intronic/intergenic
rs4923536	11	28400949	A>G,T	0.05	regulatory_region_variant	METTL15	8e-11	Tier 3: regulatory
rs12603115	17	48171632	C>A,G,T	0.05	intron_variant	SKAP1	8e-10	Tier 4: intronic/intergenic
rs1537818	1	39181366	G>A	0.05	intron_variant	MACF1	1e-09	Tier 4: intronic/intergenic
rs1444789	10	9022398	T>C	0.05	intergenic_variant	LINC02676 - LINC00709	1e-09	Tier 4: intronic/intergenic

ClinVar germline variants

7 retrieved; paginated sample, class counts are floors:

4 pathogenic, 2 uncertain significance, 1 likely pathogenic

ClinVar	Variant (HGVS)	Gene	Classification	Review
267861	46;XX;t(2;11)(q11.2;p13)dn		Pathogenic	criteria provided, single submitter
133326	NM_001371928.1(AHDC1):c.2373_2374del (p.Cys791fs)	AHDC1	Pathogenic	criteria provided, multiple submitters, no conflicts
133327	NM_001371928.1(AHDC1):c.2898del (p.Tyr967fs)	AHDC1	Pathogenic	criteria provided, single submitter
133328	NM_001371928.1(AHDC1):c.2547del (p.Ser850fs)	AHDC1	Pathogenic	criteria provided, multiple submitters, no conflicts
2570654	NM_020922.5(WNK3):c.4000dup (p.Arg1334fs)	WNK3	Likely pathogenic	criteria provided, single submitter
523307	NC_012920.1(MT-CO3):m.9355A>T	MT-CO3	Uncertain significance	criteria provided, single submitter
2571627	NM_001024383.2(NAV3):c.664C>T (p.Gln222Ter)	NAV3	Uncertain significance	criteria provided, single submitter

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 0 · Orphanet: 5 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

Orphanet rare-disease linkage (cohort genes)

Gene	Orphanet ID	Rare disease
AHDC1	Orphanet:412069	AHDC1-related intellectual disability-obstructive sleep apnea-mild dysmorphism syndrome
MT-CO3	Orphanet:104	Leber hereditary optic neuropathy
MT-CO3	Orphanet:254905	Isolated cytochrome C oxidase deficiency
MT-CO3	Orphanet:550	MELAS
MT-CO3	Orphanet:99845	Genetic recurrent myoglobinuria

Cohort genes → proteins

4 cohort genes, 4 distinct canonical proteins.

Evidence partition

Subset	Genes
multi_evidence	4

Cohort genes (full)

Symbol	HGNC	Ensembl	UniProt	Name	Evidence
WNK3	HGNC:14543	ENSG00000196632	Q9BYP7	Serine/threonine-protein kinase WNK3	clinvar
NAV3	HGNC:15998	ENSG00000067798	Q8IVL0	Neuron navigator 3	clinvar
AHDC1	HGNC:25230	ENSG00000126705	Q5TGY3	Transcription factor Gibbin	clinvar
MT-CO3	HGNC:7422	ENSG00000198938	P00414	Cytochrome c oxidase subunit 3	clinvar

Cohort function summary

Lead sentence per gene, UniProt-curated.

Symbol	Protein name	Function (lead sentence)
WNK3	Serine/threonine-protein kinase WNK3	Serine/threonine-protein kinase component of the WNK3-SPAK/OSR1 kinase cascade, which plays an important role in the regulation of electrolyte homeostasis and regulatory volume increase in response to hyperosmotic stress.
NAV3	Neuron navigator 3	Is involved in microtubule cytoskeleton organization and plays a role in cell migration.
AHDC1	Transcription factor Gibbin	Transcription factor required for the proper patterning of the epidermis, which plays a key role in early epithelial morphogenesis.
MT-CO3	Cytochrome c oxidase subunit 3	Component of the cytochrome c oxidase, the last enzyme in the mitochondrial electron transport chain which drives oxidative phosphorylation.

Protein-family classification

Druggable: 1 · Difficult: 0 · Unknown: 3 · Druggable fraction: 0.25

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

Family	Genes	Fold	FDR
Kinase	1	6.9×	0.273
Other/Unknown	3	1.3×	0.404

Per-gene assignment

Symbol	Family	Druggable?	EC	InterPro (top 3)
WNK3	Kinase	yes		Prot_kinase_dom, Ser/Thr_kinase_AS, Kinase-like_dom_sf
NAV3	Other/Unknown	no		CH_dom, AAA+_ATPase, ATPase_AAA_core
AHDC1	Other/Unknown	no		DUF4683, AHDC1
MT-CO3	Other/Unknown	no		Cyt_c_oxidase-like_su3, Cyt_c_oxidase_su3_a-hlx, Cyt_c/ubiquinol_Oxase_su3

Expression context

Cohort genes with no expression data: 0.

4 cohort genes are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

Bucket	Genes
narrow (1-5 tissues)	0
moderate (6-20)	0
broad (>20)	4
unknown	0

Top tissues across cohort

Tissue	Cohort genes
buccal mucosa cell	1
cauda epididymis	1
corpus epididymis	1
Brodmann (1909) area 23	1
cortical plate	1
middle temporal gyrus	1
Brodmann (1909) area 10	1
frontal pole	1
paraflocculus	1
endocervix	1
rectum	1
zone of skin	1

Per-gene tissue summary (top 30)

Symbol	Bgee breadth	FANTOM5 breadth	SCXA	Top tissues
WNK3	181	broad	marker	corpus epididymis, buccal mucosa cell, cauda epididymis
NAV3	232	ubiquitous	marker	middle temporal gyrus, cortical plate, Brodmann (1909) area 23
AHDC1	232	ubiquitous	marker	paraflocculus, Brodmann (1909) area 10, frontal pole
MT-CO3	134	ubiquitous	marker	zone of skin, endocervix, rectum

Protein interactions among cohort

Intra-cohort edges: 0.

Hub genes (top 10 by interactor count)

Symbol	Interactor count
MT-CO3	1,791
WNK3	1,097
NAV3	963
AHDC1	787

Structural data

PDB: 2 · AlphaFold-only: 2 · No structure: 0

Cohort genes with PDB structures (top 30)

Symbol	UniProt	PDB entries
WNK3	Q9BYP7	9
MT-CO3	P00414	3

AlphaFold-only cohort genes (top 30 by pLDDT)

Symbol	UniProt	pLDDT
NAV3	Q8IVL0	48.21
AHDC1	Q5TGY3	38.82

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 6. Enrichment computed across 4 evidence-associated genes (2 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 2 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

Pathway	Cohort genes	Fold	FDR	Sample cohort genes
Complex IV assembly	1	114.2×	0.021	MT-CO3
Cytoprotection by HMOX1	1	92.1×	0.021	MT-CO3
Stimuli-sensing channels	1	68.0×	0.021	WNK3
TP53 Regulates Metabolic Genes	1	64.9×	0.021	MT-CO3
Mitochondrial translation termination	1	54.9×	0.021	MT-CO3
Respiratory electron transport	1	47.6×	0.021	MT-CO3

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 4 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO term	Cohort genes	Fold	FDR	Sample cohort genes
positive regulation of sodium ion transmembrane transporter activity	1	2106.5×	0.010	WNK3
negative regulation of pancreatic juice secretion	1	842.6×	0.010	WNK3
respiratory chain complex IV assembly	1	601.9×	0.010	MT-CO3
monoatomic ion homeostasis	1	601.9×	0.010	WNK3
regulation of calcium ion import	1	526.6×	0.010	WNK3
regulation of monoatomic cation transmembrane transport	1	526.6×	0.010	WNK3
positive regulation of peptidyl-threonine phosphorylation	1	468.1×	0.010	WNK3
osmosensory signaling pathway	1	383.0×	0.011	WNK3
skin morphogenesis	1	351.1×	0.011	AHDC1
cellular hyperosmotic response	1	300.9×	0.011	WNK3
membraneless organelle assembly	1	280.9×	0.011	WNK3
renal sodium ion absorption	1	247.8×	0.011	WNK3
positive regulation of sodium ion transport	1	210.7×	0.012	WNK3
mitochondrial electron transport, cytochrome c to oxygen	1	191.5×	0.012	MT-CO3
positive regulation of microtubule polymerization	1	168.5×	0.012	NAV3
negative regulation of protein localization to plasma membrane	1	156.0×	0.012	WNK3
cell volume homeostasis	1	150.5×	0.012	WNK3
negative regulation of interleukin-2 production	1	145.3×	0.012	NAV3
positive regulation of calcium ion transport	1	145.3×	0.012	WNK3
mesoderm formation	1	123.9×	0.013	AHDC1
negative regulation of microtubule depolymerization	1	123.9×	0.013	NAV3
maintenance of blood-brain barrier	1	120.4×	0.013	WNK3
cellular respiration	1	108.0×	0.014	MT-CO3
positive regulation of protein localization to plasma membrane	1	68.0×	0.021	WNK3
neurogenesis	1	52.0×	0.026	NAV3
microtubule cytoskeleton organization	1	30.3×	0.043	NAV3
negative regulation of cell migration	1	27.9×	0.044	NAV3
protein localization to plasma membrane	1	27.2×	0.044	WNK3
protein phosphorylation	1	17.0×	0.068	WNK3
DNA damage response	1	13.4×	0.082	WNK3

Therapeutics

Drugs indicated for this disease

0 approved, 1 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Armodafinil	Phase 3 (in late-stage trials)

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Atomoxetine, Carbon Dioxide, Incobotulinumtoxina, Medroxyprogesterone Acetate, Montelukast, Onabotulinumtoxina, Oxybutynin.

Drug target analysis

Approved (phase 4): 0 · Phase ≥3: 0 · Phased (≥1): 1 · Undrugged: 3

Druggability breadth: 2 of 4 evidence-associated genes (50%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Top cohort targets by molecule count

Symbol	Molecules	Max phase
WNK3	1	2
NAV3	0	0
AHDC1	0	0
MT-CO3	0	0

Drugs targeting cohort genes (top 30)

Molecule	Max phase	Targets in cohort
ADAVOSERTIB	2	WNK3

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 0.

Cohort genes with ChEMBL bioactivity (full, sorted by assay count)

Symbol	Assays	Type breakdown
WNK3	142	Binding:142
MT-CO3	1	Binding:1

Cohort genes with high screening signal

≥100 ChEMBL assays — a studied-ness signal; see Therapeutics for approved-drug status.

Symbol	ChEMBL assays
WNK3	142

Pharmacogenomics

Cohort genes with a PharmGKB record: 4; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Chemical tractability of cohort targets

1 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.

Compound	Max phase	Cohort target (bioactivity)
ADAVOSERTIB	2	WNK3

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

Tier	Definition	Genes	Symbols
A	Approved (phase 4 drug)	0
B	Phased (≥1) drug, not yet approved	1	WNK3
C	Druggable family + PDB, no drug	0
D	Druggable family + AlphaFold only, no drug	0
E	Difficult family or no structure, no drug	3	NAV3, AHDC1, MT-CO3

Undrugged target profiles

3 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

Symbol	ChEMBL assays	Drugged partners (top 3)
NAV3	0	—
AHDC1	0	—
MT-CO3	1	—

Clinical trials & evidence

Clinical trials

Clinical trials: 742.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	611
PHASE4	47
PHASE2	33
PHASE3	16
PHASE2/PHASE3	11
PHASE1	11
PHASE1/PHASE2	8
EARLY_PHASE1	5

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02630121	PHASE4	RECRUITING	Effect of Oxymetazoline Hydrochloride in Combination With Fluticasone Propionate on the Apnea Hypopnea Index (AHI) in Subject With Persistent Nasal Congestion and Mild Obstructive Sleep Apnea
NCT02703220	PHASE4	RECRUITING	Sleep Apnea in Elderly
NCT02922894	PHASE4	RECRUITING	Treatment of Sleep Apnea in Patients With Cervical Spinal Cord Injury
NCT04118387	PHASE4	RECRUITING	Central Sleep Apnea : Physiologic Mechanisms to Inform Treatment
NCT05612594	PHASE4	RECRUITING	Adipose Dysfunction, Imaging, Physiology, and Outcomes With Sodium Glucose Cotransporter 2 Inhibitor (SGLT2i) for Sleep Apnea: The ADIPOSA Study
NCT05846490	PHASE4	RECRUITING	Impact of Obstructive Sleep Apnea (OSA) Treatment on Blood Pressure Control in Chronic Kidney Disease
NCT06463561	PHASE4	RECRUITING	CPAP Effect on Lipid Profile and Hyperuricemia in Patients With Dyslipidemia and Moderate-severe Obstructive Sleep Apnea
NCT06498531	PHASE4	RECRUITING	HighCycle Study: Effect of Acetazolamide on Sleep Disordered Breathing in Women Compared to Men
NCT06576830	PHASE4	RECRUITING	Optimization of Pediatric Tonsillectomy to IMprove AnaLgesia
NCT07210606	PHASE4	NOT_YET_RECRUITING	Central Apnea in Heart Failure: Physiological Mechanisms to Inform Treatment
NCT00127348	PHASE4	COMPLETED	Effect of Continuous Positive Airway Pressure (CPAP) on Hypertension and Cardiovascular Morbidity-Mortality in Patients With Sleep Apnea and no Daytime Sleepiness
NCT00299910	PHASE4	UNKNOWN	Inflammatory Response to Anti Inflammatory Therapy in Children With Sleep Disordered Breathing
NCT00424658	PHASE4	COMPLETED	Sleep Apnea. Concordance Between Non-reference and Reference Centres
NCT00487929	PHASE4	COMPLETED	Oxidative Stress and Cardiovascular Morbidity in Sleep Apnea-Hypopnea Syndrome (SAHS)
NCT00517777	PHASE4	UNKNOWN	Continuous Positive Airway Pressure in Sleep Apnea Syndrome: Effects on Metabolic Syndrome and Cardiac Damage
NCT00547937	PHASE4	COMPLETED	Sleep Apnea and Oxidative Stress and Nitric Oxide
NCT00701428	PHASE4	COMPLETED	Losartan in Hypertensive Men and Women With Sleep Apnea Before and on Continuous Positive Airway Pressure (CPAP) Treatment
NCT00765713	PHASE4	COMPLETED	Sleep Apnea-hypopnea Syndrome (SAHS) and Ventricular Arrhythmias
NCT00804349	PHASE4	COMPLETED	Treatment of Sleep Disordered Breathing In Acute Decompensated Heart Failure Patients
NCT01164631	PHASE4	COMPLETED	Pharyngeal Size in Patients With Obstructive Tonsils Under Orthodontic Treatment
NCT01505959	PHASE4	UNKNOWN	Blood Pressure Reduction Induced by CPAP in Sleep Apnea Patients at High Cardiovascular Risk : OPTISAS 2 Study
NCT01796769	PHASE4	UNKNOWN	Multidisciplinary and Coordinated Follow-up Based on a Telemonitoring Web Platform for Improving CPAP Compliance in Low Cardiovascular Risk Sleep Apnea Patients : OPTISAS 1 Study
NCT01801150	PHASE4	COMPLETED	CPAP in Diabetes Type 2 Patients With Sleep Apnea
NCT01807897	PHASE4	COMPLETED	Oxygen Versus PAP for Sleep Apnea in Heart Failure
NCT01861145	PHASE4	WITHDRAWN	Intranasal Steroids for the Treatment of Nocturnal Enuresis With Associated Obstructive Sleep Apnea
NCT02045173	PHASE4	COMPLETED	Automate Detection of Sleep Apnea by ApneascanTM
NCT02058823	PHASE4	TERMINATED	Intermittent Hypoxia 2: Cardiovascular and Metabolism
NCT02295202	PHASE4	COMPLETED	Impact of Obstructive Sleep Apnea Treatment in Patients With Metabolic Syndrome
NCT02296840	PHASE4	TERMINATED	Post-operative Pain Control After Pediatric Adenotonsillectomy
NCT02398032	PHASE4	COMPLETED	CPAP in SAHS Patients With Hypertension
NCT02426424	PHASE4	WITHDRAWN	Effect Of Early C-PAP Treatment For Sleep Apnea On Rehabilitation Of Stroke Patients
NCT02566226	PHASE4	COMPLETED	Impact of Intrathecal Morphine on Sleep Apnea Syndrome
NCT02643979	PHASE4	TERMINATED	Ketamine and Propofol Combination Versus Propofol for Upper Gastrointestinal Endoscopy
NCT02717780	PHASE4	COMPLETED	Short Life Agents in Balanced Anesthesia on Obstructive Sleep Apnea Syndrome
NCT02816762	PHASE4	COMPLETED	CPAP Effect on Albuminuria in Patients With Diabetic Nephropathy and Obstructive Sleep Apnea
NCT02874313	PHASE4	COMPLETED	CPAP Effect on the Progression of Diabetic Retinopathy in Patients With Sleep Apnea
NCT02916160	PHASE4	COMPLETED	Sacubitril-valsartan and Heart Failure Patients : the ENTRESTO-SAS Study
NCT03011294	PHASE4	COMPLETED	Cardiovascular Impact, Quality e Quantity of Sleep in Bed Partners of Patients With Obstructive Sleep Apnea
NCT03335904	PHASE4	COMPLETED	AT1R Blockade and Periodic Breathing During Sleep in Hypoxia
NCT03454217	PHASE4	COMPLETED	Impact of Tramadol and Oxycodone on Sleep Apnea

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
ACETAZOLAMIDE	4	8
MONTELUKAST	4	5
LOSARTAN	4	4
TRAZODONE	4	4
ARMODAFINIL	4	3
DEXTROMETHORPHAN	4	3
OXYBUTYNIN	4	3
OXYGEN	4	3
OXYMETAZOLINE	4	3
ATOMOXETINE	4	2
BUSPIRONE	4	2
ESZOPICLONE	4	2
KETOROLAC	4	2
METOPROLOL	4	2
ZOLPIDEM	4	2
ZOPICLONE	4	2
AMLODIPINE	4	1
BETAMETHASONE	4	1
BEXAGLIFLOZIN	4	1
BOSENTAN	4	1
CYCLOSERINE	4	1
DESFLURANE	4	1
DIMETHYL FUMARATE	4	1
FENOFIBRATE	4	1
FINASTERIDE	4	1
HYDROMORPHONE	4	1
HYDROXYCHLOROQUINE	4	1
IBUPROFEN	4	1
MEDROXYPROGESTERONE ACETATE	4	1
METHADONE	4	1